Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04JDQ
|
|||
| Former ID |
DNC005426
|
|||
| Drug Name |
6-Furan-2-yl-9-phenethyl-9H-purin-2-ylamine
|
|||
| Synonyms |
CHEMBL194383; 6-Furan-2-yl-9-phenethyl-9H-purin-2-ylamine; SCHEMBL3272682
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H15N5O
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)CCN2C=NC3=C(N=C(N=C32)N)C4=CC=CO4
|
|||
| InChI |
1S/C17H15N5O/c18-17-20-14(13-7-4-10-23-13)15-16(21-17)22(11-19-15)9-8-12-5-2-1-3-6-12/h1-7,10-11H,8-9H2,(H2,18,20,21)
|
|||
| InChIKey |
LOCNLYLIABVQFH-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A2a receptor (ADORA2A) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Rap1 signaling pathway | |||
| Calcium signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Parkinson's disease | ||||
| Alcoholism | ||||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | |||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| Reactome | NGF-independant TRKA activation | |||
| Adenosine P1 receptors | ||||
| G alpha (s) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Nucleotide GPCRs | |||
| Monoamine Transport | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| NGF signalling via TRKA from the plasma membrane | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2119-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.